董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Aaron Fletcher | 男 | Director | 41 | 5.95万美元 | 606.05 | 2021-10-07 |
| Aaron Fletcher | 男 | Director | 41 | 未披露 | 未持股 | 2021-10-07 |
| Peggy Wallace | 女 | Director | 64 | 6.10万美元 | 9.85 | 2021-10-07 |
| Mark H. Breedlove | 男 | Director | 64 | 1.15万美元 | 未持股 | 2021-10-07 |
| Jack A. Khattar | 男 | Director, Chairman of the Board | 59 | 9.50万美元 | 7.91 | 2021-10-07 |
| Brett P. Monia | 男 | Director | 59 | 6.45万美元 | 7.91 | 2021-10-07 |
| Lisa Ricciardi | 女 | Chief Executive Officer, President and Director | 61 | 145.96万美元 | 256.57 | 2021-10-07 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| James M. O'Brien | 男 | Chief Financial Officer | 54 | 41.82万美元 | 未持股 | 2021-10-07 |
| James M. O'Brien | 男 | Chief Financial Officer | 54 | 未披露 | 未持股 | 2021-10-07 |
| Lisa Ricciardi | 女 | Chief Executive Officer, President and Director | 61 | 145.96万美元 | 256.57 | 2021-10-07 |
董事简历
中英对照 | 中文 | 英文- Aaron Fletcher
-
Aaron Fletcher自2018年1月起担任董事会成员，自2018年12月起担任董事会主席。自2012年以来，Fletcher博士一直担任BIOS Research的创始人兼总裁，该公司是一家金融服务公司，为机构公司和大型家族办公室量身定制梦百合行业的公共股票研究。自2014年以来，Fletcher博士还担任BIOS Partners，LP的管理合伙人，该公司是一家风险投资公司，专注于投资早期和成长阶段的生物技术和医疗设备公司。弗莱彻博士还担任LTI公司、Cue Biopharma公司（纳斯达克市场代码:CUE）、SWK Holdings Corporation（纳斯达克市场代码:SWKH）、Actuate Therapeutics公司、Abilitech Medical公司和CogRx Therapeutics公司的董事。Fletcher博士拥有科罗拉多州立大学（Colorado State University）生物化学博士学位，并担任达拉斯浸信会大学（Dallas Baptist University）客座教授。Fletcher博士在生物技术/梦百合股票行业担任了十多年的独立顾问。
Aaron Fletcher has served as a member of our Board since January 2018 and has served as the Chairman of the Board since December 2018. Since 2012 Dr. Fletcher has served as founder and President of Bios Research, a financial services firm that provides public equity research in the healthcare industry tailored to institutional firms and large family offices. Since 2014 Dr. Fletcher has also served as Managing Partner of Bios Partners, LP, a venture capital firm focused on investment in early-stage and growth-stage biotech and medical device companies. Dr. Fletcher also serves as a director of LTI, Cue Biopharma, Inc Nasdaq: CUE, SWK Holdings Corporation (Nasdaq: SWKH), Actuate Therapeutics, AbiliTech Medical, and CogRx Therapeutics. Dr. Fletcher holds a Ph.D. in Biochemistry from Colorado State University and serves as a visiting professor at Dallas Baptist University. Dr. Fletcher has worked as an independent consultant for the biotech/healthcare equity industry for over ten years. - Aaron Fletcher自2018年1月起担任董事会成员，自2018年12月起担任董事会主席。自2012年以来，Fletcher博士一直担任BIOS Research的创始人兼总裁，该公司是一家金融服务公司，为机构公司和大型家族办公室量身定制梦百合行业的公共股票研究。自2014年以来，Fletcher博士还担任BIOS Partners，LP的管理合伙人，该公司是一家风险投资公司，专注于投资早期和成长阶段的生物技术和医疗设备公司。弗莱彻博士还担任LTI公司、Cue Biopharma公司（纳斯达克市场代码:CUE）、SWK Holdings Corporation（纳斯达克市场代码:SWKH）、Actuate Therapeutics公司、Abilitech Medical公司和CogRx Therapeutics公司的董事。Fletcher博士拥有科罗拉多州立大学（Colorado State University）生物化学博士学位，并担任达拉斯浸信会大学（Dallas Baptist University）客座教授。Fletcher博士在生物技术/梦百合股票行业担任了十多年的独立顾问。
- Aaron Fletcher has served as a member of our Board since January 2018 and has served as the Chairman of the Board since December 2018. Since 2012 Dr. Fletcher has served as founder and President of Bios Research, a financial services firm that provides public equity research in the healthcare industry tailored to institutional firms and large family offices. Since 2014 Dr. Fletcher has also served as Managing Partner of Bios Partners, LP, a venture capital firm focused on investment in early-stage and growth-stage biotech and medical device companies. Dr. Fletcher also serves as a director of LTI, Cue Biopharma, Inc Nasdaq: CUE, SWK Holdings Corporation (Nasdaq: SWKH), Actuate Therapeutics, AbiliTech Medical, and CogRx Therapeutics. Dr. Fletcher holds a Ph.D. in Biochemistry from Colorado State University and serves as a visiting professor at Dallas Baptist University. Dr. Fletcher has worked as an independent consultant for the biotech/healthcare equity industry for over ten years.
- Aaron Fletcher
-
暂无中文简介
Aaron Fletcher has served as a member of our board of directors since July 2015. In 2014 Dr. Fletcher founded Bios Partners, LP, a biotech venture capital firm, and has served as its Managing Partner since then. In 2012 Dr. Fletcher founded Bios Research, LLC, a financial services firm that provides public equity research in the healthcare space tailored to institutional firms and large family offices. He also currently serves as a director of Cue Biopharma NYSE: CUE since October 2019 SKW Holdings Corporation (Nasdaq: SWKH) since August 2019 TFF Pharmaceuticals (Nasdaq: TFFP) since March 2018 where he serves as the chairman of the board, AbiliTech Medical, Inc. since November 2016 Actuate Therapeutics, Inc. since January 2015 where he serves as the chairman of the board, and LTI since August 2014. Dr. Fletcher has also served as a professor at Dallas Baptist University since 2008 where he teaches biochemistry, bioethics and cell biology.Dr. Fletcher holds a BS in Biology from York College and received his Ph.D. in Biochemistry from Colorado State University. -
暂无中文简介
- Aaron Fletcher has served as a member of our board of directors since July 2015. In 2014 Dr. Fletcher founded Bios Partners, LP, a biotech venture capital firm, and has served as its Managing Partner since then. In 2012 Dr. Fletcher founded Bios Research, LLC, a financial services firm that provides public equity research in the healthcare space tailored to institutional firms and large family offices. He also currently serves as a director of Cue Biopharma NYSE: CUE since October 2019 SKW Holdings Corporation (Nasdaq: SWKH) since August 2019 TFF Pharmaceuticals (Nasdaq: TFFP) since March 2018 where he serves as the chairman of the board, AbiliTech Medical, Inc. since November 2016 Actuate Therapeutics, Inc. since January 2015 where he serves as the chairman of the board, and LTI since August 2014. Dr. Fletcher has also served as a professor at Dallas Baptist University since 2008 where he teaches biochemistry, bioethics and cell biology.Dr. Fletcher holds a BS in Biology from York College and received his Ph.D. in Biochemistry from Colorado State University.
- Peggy Wallace
-
Peggy Wallace自2016年9月起担任我们的董事会成员。自2011年和2008年以来，她分别担任Golden Seeds，LLC和Golden Seeds Funds（一家投资公司）的联席首席执行官和管理合伙人，在此之前，她从2005年到2008年担任董事总经理。自2006年以来，Wallace女士目前是Chromis Technologies（光纤产品供应商）的董事会成员。Wallace女士在乔治华盛顿大学获得文学学士学位。
Peggy Wallace has served as member of our board of directors since September 2016. Ms. Wallace has served as Co-Chief Executive Officer and Managing Partner of Golden Seeds, LLC and Golden Seeds Funds, an investment company, since 2011 and 2008 respectively, prior to which she served as a Managing Director from 2005 to 2008. Ms. Wallace currently is a member of the board of directors of Chromis Technologies, a fiber optic products supplier, since 2006.Ms. Wallace received her Bachelor of Arts from George Washington University. - Peggy Wallace自2016年9月起担任我们的董事会成员。自2011年和2008年以来，她分别担任Golden Seeds，LLC和Golden Seeds Funds（一家投资公司）的联席首席执行官和管理合伙人，在此之前，她从2005年到2008年担任董事总经理。自2006年以来，Wallace女士目前是Chromis Technologies（光纤产品供应商）的董事会成员。Wallace女士在乔治华盛顿大学获得文学学士学位。
- Peggy Wallace has served as member of our board of directors since September 2016. Ms. Wallace has served as Co-Chief Executive Officer and Managing Partner of Golden Seeds, LLC and Golden Seeds Funds, an investment company, since 2011 and 2008 respectively, prior to which she served as a Managing Director from 2005 to 2008. Ms. Wallace currently is a member of the board of directors of Chromis Technologies, a fiber optic products supplier, since 2006.Ms. Wallace received her Bachelor of Arts from George Washington University.
- Mark H. Breedlove
-
Mark H.Breedlove自2011年1月起担任公司董事会成员。2010年以来，他曾担任the Breedlove Family Limited Partnership（家庭投资合伙企业）的普通合伙人，在那里他负责所有直接投资活动，包括投资生命科学公司的战略。自2003年以来，Breedlove先生还担任Keystone Profiles，Ltd.（一家钢铁制造公司）的总裁兼首席执行官。从1999年到2000年，Breedlove先生担任Qualitor Inc.的总裁、首席运营官和董事会成员，这是一家售后汽车零部件公司。Breedlove拥有宾夕法尼亚州立大学的工商管理和金融理学学士学位。他还获得了密歇根大学的工商管理硕士学位，重点是金融。
Mark H. Breedlove has served as member of our board of directors since January 2011. Since 2010 Mr. Breedlove served as General Partner for the Breedlove Family Limited Partnership, a family investment partnership, where he is responsible for all direct investment activity, including a strategy of investing in life sciences companies. Since 2003 Mr. Breedlove also has served as President and CEO of Keystone Profiles, Ltd., a steel manufacturing company. From 1999 to 2000 Mr. Breedlove served as President, COO and a member of the Board of Directors of Qualitor Inc., an aftermarket vehicle parts company.Mr. Breedlove has a Bachelor of Science degree in Business Administration, Finance, from the Pennsylvania State University. He also has an MBA with an emphasis in Finance from the University of Michigan. - Mark H.Breedlove自2011年1月起担任公司董事会成员。2010年以来，他曾担任the Breedlove Family Limited Partnership（家庭投资合伙企业）的普通合伙人，在那里他负责所有直接投资活动，包括投资生命科学公司的战略。自2003年以来，Breedlove先生还担任Keystone Profiles，Ltd.（一家钢铁制造公司）的总裁兼首席执行官。从1999年到2000年，Breedlove先生担任Qualitor Inc.的总裁、首席运营官和董事会成员，这是一家售后汽车零部件公司。Breedlove拥有宾夕法尼亚州立大学的工商管理和金融理学学士学位。他还获得了密歇根大学的工商管理硕士学位，重点是金融。
- Mark H. Breedlove has served as member of our board of directors since January 2011. Since 2010 Mr. Breedlove served as General Partner for the Breedlove Family Limited Partnership, a family investment partnership, where he is responsible for all direct investment activity, including a strategy of investing in life sciences companies. Since 2003 Mr. Breedlove also has served as President and CEO of Keystone Profiles, Ltd., a steel manufacturing company. From 1999 to 2000 Mr. Breedlove served as President, COO and a member of the Board of Directors of Qualitor Inc., an aftermarket vehicle parts company.Mr. Breedlove has a Bachelor of Science degree in Business Administration, Finance, from the Pennsylvania State University. He also has an MBA with an emphasis in Finance from the University of Michigan.
- Jack A. Khattar
-
Jack A. Khattar是公司的创始人并自2005年以来担任总裁，首席执行官，秘书兼董事。Khattar先生从1999年到2005年担任过各种职务，Shire Laboratories Inc.（Shire plc.药物输送子公司）的董事会成员，总裁兼首席执行官。从1999年到2004年他还是Shire plc.执行委员会的成员。此前，Khattar先生担任CIMA Labs Inc.的执行官和管理委员会主席。CIMA是药物递送公司，目前是Cephalon的分部。他在CIMA还负责业务开发，包括CIMA许可技术，企业联盟和战略规划。1995年加入CIMA之前Khattar先生在Merck & Co., Novartis, Playtex和Kodak担任一些营销和业务发展职位，其地点包括美国、欧洲和中东。Khattar先生在贝鲁特美国大学（American University of Beirut）获得了市场营销的工商管理学士学位，在宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania）获得工商管理硕士学位。
Jack A. Khattar has served as member of board of directors since July 2020 and was appointed chairman in April 2021. Mr. Khattar founded Supernus Pharmaceuticals, Inc., a pharmaceutical company Nasdaq:SUPN, in 2005 and has served as its President, Chief Executive Officer, Secretary and director since then. Since June 2016 Mr. Khattar has served as a member of the board of directors of scPharmaceuticals Inc., a pharmaceutical company (Nasdaq:SCPH), and has served as its chairperson since June 2016. From 1999 to 2005 Mr. Khattar served in various positions during that time as a board member, President and Chief Executive Officer of Shire Laboratories Inc., the drug delivery subsidiary of Shire plc. From 1999 to 2004 he also served as a member of Shire plc's Executive Committee. Prior to that, Mr. Khattar served as an executive officer and the chairman of the Management Committee at CIMA Labs Inc., a drug delivery company where he was also responsible for business development, corporate alliances and strategic planning. Prior to joining CIMA in 1995 Mr. Khattar held several marketing and business development positions at Merck & Co., Novartis International AG, Playtex and Kodak Company in various locations, including the United States, Europe and the Middle East. Mr. Khattar currently serves on the board of Navitor Pharmaceuticals, Inc., a private company, since 2020 and Supernus Pharmaceuticals (Nasdaq: SUPN) since 2005. He previously served on the board of Rockville Economic Development, Inc. from 2003 to 2013 and Prevacus, Inc., a privately held development stage biotechnology company from 2015 to 2020. Mr. Khattar has also served on the Advisory Board of New Rhein Healthcare, a private equity firm, since 2019.Mr. Khattar earned his degrees in Marketing with a BBA from American University of Beirut and an MBA from the Wharton School of the University of Pennsylvania. - Jack A. Khattar是公司的创始人并自2005年以来担任总裁，首席执行官，秘书兼董事。Khattar先生从1999年到2005年担任过各种职务，Shire Laboratories Inc.（Shire plc.药物输送子公司）的董事会成员，总裁兼首席执行官。从1999年到2004年他还是Shire plc.执行委员会的成员。此前，Khattar先生担任CIMA Labs Inc.的执行官和管理委员会主席。CIMA是药物递送公司，目前是Cephalon的分部。他在CIMA还负责业务开发，包括CIMA许可技术，企业联盟和战略规划。1995年加入CIMA之前Khattar先生在Merck & Co., Novartis, Playtex和Kodak担任一些营销和业务发展职位，其地点包括美国、欧洲和中东。Khattar先生在贝鲁特美国大学（American University of Beirut）获得了市场营销的工商管理学士学位，在宾夕法尼亚大学沃顿商学院（Wharton School of the University of Pennsylvania）获得工商管理硕士学位。
- Jack A. Khattar has served as member of board of directors since July 2020 and was appointed chairman in April 2021. Mr. Khattar founded Supernus Pharmaceuticals, Inc., a pharmaceutical company Nasdaq:SUPN, in 2005 and has served as its President, Chief Executive Officer, Secretary and director since then. Since June 2016 Mr. Khattar has served as a member of the board of directors of scPharmaceuticals Inc., a pharmaceutical company (Nasdaq:SCPH), and has served as its chairperson since June 2016. From 1999 to 2005 Mr. Khattar served in various positions during that time as a board member, President and Chief Executive Officer of Shire Laboratories Inc., the drug delivery subsidiary of Shire plc. From 1999 to 2004 he also served as a member of Shire plc's Executive Committee. Prior to that, Mr. Khattar served as an executive officer and the chairman of the Management Committee at CIMA Labs Inc., a drug delivery company where he was also responsible for business development, corporate alliances and strategic planning. Prior to joining CIMA in 1995 Mr. Khattar held several marketing and business development positions at Merck & Co., Novartis International AG, Playtex and Kodak Company in various locations, including the United States, Europe and the Middle East. Mr. Khattar currently serves on the board of Navitor Pharmaceuticals, Inc., a private company, since 2020 and Supernus Pharmaceuticals (Nasdaq: SUPN) since 2005. He previously served on the board of Rockville Economic Development, Inc. from 2003 to 2013 and Prevacus, Inc., a privately held development stage biotechnology company from 2015 to 2020. Mr. Khattar has also served on the Advisory Board of New Rhein Healthcare, a private equity firm, since 2019.Mr. Khattar earned his degrees in Marketing with a BBA from American University of Beirut and an MBA from the Wharton School of the University of Pennsylvania.
- Brett P. Monia
-
Brett P. Monia ，2012年1月，他晋升为药物研发部门和公司发展部门的高级副总裁。自2009年2月至2012年1月，他担任我们的药物研发部门和公司发展部门的副总裁；自2000年10月至2009年2月，他担任临床前药物开发部门的副总裁。自1989年10月至2000年10月，他在分子药理学部门担任过许多职务。
Brett P. Monia has served as a member of our board of directors since October 2020. Dr. Monia founded Ionis Pharmaceuticals, Inc., a biotechnology company Nasdaq: IONS, in 1989 and has served as its Chief Executive Officer since January 2020 after serving as the Chief Operating Officer and Senior Vice President since 2018 as a member of its board of directors since March 2019 and in various other positions with the company since its founding. He is also a director of Dynacure LTD, a clinical stage drug development company, since 2016.Dr. Monia received his Bachelor of Science in Biology, Biological Sciences and Chemistry from Stockton State College and a Ph.D. in Pharmacology from the University of Pennsylvania. - Brett P. Monia ，2012年1月，他晋升为药物研发部门和公司发展部门的高级副总裁。自2009年2月至2012年1月，他担任我们的药物研发部门和公司发展部门的副总裁；自2000年10月至2009年2月，他担任临床前药物开发部门的副总裁。自1989年10月至2000年10月，他在分子药理学部门担任过许多职务。
- Brett P. Monia has served as a member of our board of directors since October 2020. Dr. Monia founded Ionis Pharmaceuticals, Inc., a biotechnology company Nasdaq: IONS, in 1989 and has served as its Chief Executive Officer since January 2020 after serving as the Chief Operating Officer and Senior Vice President since 2018 as a member of its board of directors since March 2019 and in various other positions with the company since its founding. He is also a director of Dynacure LTD, a clinical stage drug development company, since 2016.Dr. Monia received his Bachelor of Science in Biology, Biological Sciences and Chemistry from Stockton State College and a Ph.D. in Pharmacology from the University of Pennsylvania.
- Lisa Ricciardi
-
Lisa Ricciardi自2014年3月以来一直是我们的董事之一。她目前是爱尔兰都柏林的药物医疗集团的董事会成员并长期担任Sepracor董事会的一员。自2012年7月以来，她做了Davita RX公司（提供全面肾保健服务的制药公司）的顾问。从2010年10月到2012年6月她担任Medco Health Solutions, Inc.的业务发展高级副总裁和 Essex Woodlands Health Ventures合资企业合伙人。她还多次担任Pfizer公司高级管理职位，包括许可和发展部门高级副总裁，执行了超过25个与跨国公司和生物技术公司合作的项目，以及全球制药部门的几个关键的产品发布。她获得了芝加哥大学的工商管理硕士学位和卫斯理大学学士学位。
Lisa Ricciardi has served as our Chief Executive Officer and President since March 2020 and as a member of our board of directors since March 2019. From July 2018 to October 2019 she served as CEO of Suono Bio, a biotech company based on Langer Labs MIT technology. Prior to her position at Suono Bio, Ms. Ricciardi was a retained executive for BioBusiness Links from November 2015 to June 2018 where she performed interim operating executive and advisory board roles. She served as the Senior Vice President, Global Corporate & Business Development of Foundation Medicine from July 2014 to November 2015 and Senior Vice President, US and International Business Development of Express Scripts from October 2010 to October 2012 and in both cases, led deal teams to sell the two companies. Ms. Ricciardi was in the commercial division of Pfizer Inc., taking three drugs to launch before being appointed by the Chairman to run Global Business Development. Ms. Ricciardi previously served on the boards of Contrafect (Nasdaq: CFRX), Chimerix (Nasdaq: CMRX), United Drug Healthcare Group, PLC (LSE: UDG) and Sepracor (Nasdaq: SEPR). She was appointed as the executive in residence at Columbia Technology Ventures in January 2020.Ms. Ricciardi earned a Bachelor of Arts degree cum laude in English and Religion from Wesleyan University and an MBA from the University of Chicago Booth School of Management. - Lisa Ricciardi自2014年3月以来一直是我们的董事之一。她目前是爱尔兰都柏林的药物医疗集团的董事会成员并长期担任Sepracor董事会的一员。自2012年7月以来，她做了Davita RX公司（提供全面肾保健服务的制药公司）的顾问。从2010年10月到2012年6月她担任Medco Health Solutions, Inc.的业务发展高级副总裁和 Essex Woodlands Health Ventures合资企业合伙人。她还多次担任Pfizer公司高级管理职位，包括许可和发展部门高级副总裁，执行了超过25个与跨国公司和生物技术公司合作的项目，以及全球制药部门的几个关键的产品发布。她获得了芝加哥大学的工商管理硕士学位和卫斯理大学学士学位。
- Lisa Ricciardi has served as our Chief Executive Officer and President since March 2020 and as a member of our board of directors since March 2019. From July 2018 to October 2019 she served as CEO of Suono Bio, a biotech company based on Langer Labs MIT technology. Prior to her position at Suono Bio, Ms. Ricciardi was a retained executive for BioBusiness Links from November 2015 to June 2018 where she performed interim operating executive and advisory board roles. She served as the Senior Vice President, Global Corporate & Business Development of Foundation Medicine from July 2014 to November 2015 and Senior Vice President, US and International Business Development of Express Scripts from October 2010 to October 2012 and in both cases, led deal teams to sell the two companies. Ms. Ricciardi was in the commercial division of Pfizer Inc., taking three drugs to launch before being appointed by the Chairman to run Global Business Development. Ms. Ricciardi previously served on the boards of Contrafect (Nasdaq: CFRX), Chimerix (Nasdaq: CMRX), United Drug Healthcare Group, PLC (LSE: UDG) and Sepracor (Nasdaq: SEPR). She was appointed as the executive in residence at Columbia Technology Ventures in January 2020.Ms. Ricciardi earned a Bachelor of Arts degree cum laude in English and Religion from Wesleyan University and an MBA from the University of Chicago Booth School of Management.
高管简历
中英对照 | 中文 | 英文- James M. O'Brien
James M. O'Brien担任财务部的高级副总裁，他于2014年2月加入恩佐生化公司（Enzo Biochem, Inc.），并负责领导并管理Enzo Biochem, Inc.公司与业务单元的财务职能部门的所有业务活动。O'Brien先生担任过制药、消费产品与制造行业内的大型和小型跨国公众公司的公司与业务单元的预算与预测、美国证交会报告、内控与会计操作等部门的领导职位。从2010年到2013年，O'Brien先生担任阿特维斯制药公司（Actavis, plc）的副总裁兼公司财务总监，形式上的公司为华生制药公司（Watson Pharmaceuticals），这是一家全球性的专业制药公司。从1998年到2010年，O'Brien先生担任过Nycomed US、Aptuit, Inc.、普度制药公司（Purdue Pharma LLP）与百时美施贵宝公司（Bristol Myers Squibb Company）的高级财务领导职位。从1988年到1998年，O'Brien先生在普华永道会计师事务所（PricewaterhouseCoopers LLP）任职。他在乔治华盛顿大学（George Washington University）获得文学学士学位，并在福特汉姆大学（Fordham University）获得工商管理硕士学位。O'Brien先生是一位注册会计师。
James M. O'Brien, Senior Vice President, Finance joined Enzo Biochem, Inc. in February 2014 and is responsible for leading and managing all activities for Enzo Biochem, Inc. Corporate and Business Unit Financial functions. Mr. O'Brien has held leadership positions for Corporate and Business Unit budgeting and forecasting, SEC Reporting, Internal Controls and Accounting Operations for large and small multi-national public companies in pharmaceutical, consumer products and manufacturing industries. From 2010 to 2013 Mr. O'Brien was Vice President and Corporate Controller for Actavis, plc. formally Watson Pharmaceuticals a global specialty pharmaceutical company. From 1998 to 2010 Mr. O'Brien held senior level Finance leadership roles at Nycomed US, Aptuit, Inc., Purdue Pharma LLP and Bristol Myers Squibb Company. From 1988 to 1998 Mr. O'Brien was with PricewaterhouseCoopers LLP. He received his Bachelor of Arts degree from George Washington University and his Master of Business Administration from Fordham University. Mr. O'Brien is a Certified Public Accountant.- James M. O'Brien担任财务部的高级副总裁，他于2014年2月加入恩佐生化公司（Enzo Biochem, Inc.），并负责领导并管理Enzo Biochem, Inc.公司与业务单元的财务职能部门的所有业务活动。O'Brien先生担任过制药、消费产品与制造行业内的大型和小型跨国公众公司的公司与业务单元的预算与预测、美国证交会报告、内控与会计操作等部门的领导职位。从2010年到2013年，O'Brien先生担任阿特维斯制药公司（Actavis, plc）的副总裁兼公司财务总监，形式上的公司为华生制药公司（Watson Pharmaceuticals），这是一家全球性的专业制药公司。从1998年到2010年，O'Brien先生担任过Nycomed US、Aptuit, Inc.、普度制药公司（Purdue Pharma LLP）与百时美施贵宝公司（Bristol Myers Squibb Company）的高级财务领导职位。从1988年到1998年，O'Brien先生在普华永道会计师事务所（PricewaterhouseCoopers LLP）任职。他在乔治华盛顿大学（George Washington University）获得文学学士学位，并在福特汉姆大学（Fordham University）获得工商管理硕士学位。O'Brien先生是一位注册会计师。
- James M. O'Brien, Senior Vice President, Finance joined Enzo Biochem, Inc. in February 2014 and is responsible for leading and managing all activities for Enzo Biochem, Inc. Corporate and Business Unit Financial functions. Mr. O'Brien has held leadership positions for Corporate and Business Unit budgeting and forecasting, SEC Reporting, Internal Controls and Accounting Operations for large and small multi-national public companies in pharmaceutical, consumer products and manufacturing industries. From 2010 to 2013 Mr. O'Brien was Vice President and Corporate Controller for Actavis, plc. formally Watson Pharmaceuticals a global specialty pharmaceutical company. From 1998 to 2010 Mr. O'Brien held senior level Finance leadership roles at Nycomed US, Aptuit, Inc., Purdue Pharma LLP and Bristol Myers Squibb Company. From 1988 to 1998 Mr. O'Brien was with PricewaterhouseCoopers LLP. He received his Bachelor of Arts degree from George Washington University and his Master of Business Administration from Fordham University. Mr. O'Brien is a Certified Public Accountant.
- James M. O'Brien
James M. O’Brien自2019年10月起担任我们的首席财务官。从2014年2月至2019年10月，奥布莱恩先生担任Enzo Biochem, Inc.财务执行副总裁纽约证券交易所:Enz，一家为医学界提供参考实验室服务的生物技术公司。从2010年11月到2013年6月，O’Brien先生担任眼力健制药公司（前身为Actavis plc.）的副总裁兼公司财务总监，该公司现已被AbbVie（纽约证券交易所代码:ABBV）收购，这是一家制药公司。从2010年1月到2010年8月，他还曾担任Takeda Pharmaceuticals（纽约证券交易所代码:TAK）（以前称为Nycomed）的副总裁，从2008年1月到2009年8月，担任USI Holdings的首席会计官，并担任Aptuit的副总裁兼公司财务总监，一家Evotec公司（法兰克福证券交易所代码:EVT）和制药服务提供商，从2005年7月到2007年12月。在职业生涯的早期阶段，O’Brien先生还在Purdue Pharma，Bristol-Myers Squibb和PricewaterhouseCoopers担任领导职务。奥布莱恩是一名注册会计师，拥有乔治华盛顿大学的会计学士学位和福特汉姆大学的工商管理硕士学位。
James M. O'Brien has served as our Chief Financial Officer since October 2019. From February 2014 to October 2019 Mr. O'Brien served as Executive Vice President of finance for Enzo Biochem, Inc. NYSE: ENZ, a biotechnology company providing reference laboratory services to the medical community. From November 2010 to June 2013 Mr. O'Brien served as Vice President and Corporate Controller for Allergan, Inc., (formerly known as Actavis plc.) which has now been acquired by Abbvie (NYSE: ABBV), a pharmaceutical company. He also previously served as a Vice President at Takeda Pharmaceuticals (NYSE: TAK) (formerly known as Nycomed) from January 2010 to August 2010 Chief Accounting Officer at USI Holdings from January 2008 to August 2009 and Vice President and Corporate Controller at Aptuit, an Evotec company (Frankfurt Stock Exchange: EVT) and pharmaceutical services provider, from July 2005 to December 2007. Mr. O'Brien also held leadership roles at Purdue Pharma, Bristol-Myers Squibb and PricewaterhouseCoopers in the earlier stages of his career.Mr. O'Brien is a certified public accountant (CPA) with a Bachelor of Accountancy from George Washington University and an MBA from Fordham University.- James M. O’Brien自2019年10月起担任我们的首席财务官。从2014年2月至2019年10月，奥布莱恩先生担任Enzo Biochem, Inc.财务执行副总裁纽约证券交易所:Enz，一家为医学界提供参考实验室服务的生物技术公司。从2010年11月到2013年6月，O’Brien先生担任眼力健制药公司（前身为Actavis plc.）的副总裁兼公司财务总监，该公司现已被AbbVie（纽约证券交易所代码:ABBV）收购，这是一家制药公司。从2010年1月到2010年8月，他还曾担任Takeda Pharmaceuticals（纽约证券交易所代码:TAK）（以前称为Nycomed）的副总裁，从2008年1月到2009年8月，担任USI Holdings的首席会计官，并担任Aptuit的副总裁兼公司财务总监，一家Evotec公司（法兰克福证券交易所代码:EVT）和制药服务提供商，从2005年7月到2007年12月。在职业生涯的早期阶段，O’Brien先生还在Purdue Pharma，Bristol-Myers Squibb和PricewaterhouseCoopers担任领导职务。奥布莱恩是一名注册会计师，拥有乔治华盛顿大学的会计学士学位和福特汉姆大学的工商管理硕士学位。
- James M. O'Brien has served as our Chief Financial Officer since October 2019. From February 2014 to October 2019 Mr. O'Brien served as Executive Vice President of finance for Enzo Biochem, Inc. NYSE: ENZ, a biotechnology company providing reference laboratory services to the medical community. From November 2010 to June 2013 Mr. O'Brien served as Vice President and Corporate Controller for Allergan, Inc., (formerly known as Actavis plc.) which has now been acquired by Abbvie (NYSE: ABBV), a pharmaceutical company. He also previously served as a Vice President at Takeda Pharmaceuticals (NYSE: TAK) (formerly known as Nycomed) from January 2010 to August 2010 Chief Accounting Officer at USI Holdings from January 2008 to August 2009 and Vice President and Corporate Controller at Aptuit, an Evotec company (Frankfurt Stock Exchange: EVT) and pharmaceutical services provider, from July 2005 to December 2007. Mr. O'Brien also held leadership roles at Purdue Pharma, Bristol-Myers Squibb and PricewaterhouseCoopers in the earlier stages of his career.Mr. O'Brien is a certified public accountant (CPA) with a Bachelor of Accountancy from George Washington University and an MBA from Fordham University.
- Lisa Ricciardi
Lisa Ricciardi自2014年3月以来一直是我们的董事之一。她目前是爱尔兰都柏林的药物医疗集团的董事会成员并长期担任Sepracor董事会的一员。自2012年7月以来，她做了Davita RX公司（提供全面肾保健服务的制药公司）的顾问。从2010年10月到2012年6月她担任Medco Health Solutions, Inc.的业务发展高级副总裁和 Essex Woodlands Health Ventures合资企业合伙人。她还多次担任Pfizer公司高级管理职位，包括许可和发展部门高级副总裁，执行了超过25个与跨国公司和生物技术公司合作的项目，以及全球制药部门的几个关键的产品发布。她获得了芝加哥大学的工商管理硕士学位和卫斯理大学学士学位。
Lisa Ricciardi has served as our Chief Executive Officer and President since March 2020 and as a member of our board of directors since March 2019. From July 2018 to October 2019 she served as CEO of Suono Bio, a biotech company based on Langer Labs MIT technology. Prior to her position at Suono Bio, Ms. Ricciardi was a retained executive for BioBusiness Links from November 2015 to June 2018 where she performed interim operating executive and advisory board roles. She served as the Senior Vice President, Global Corporate & Business Development of Foundation Medicine from July 2014 to November 2015 and Senior Vice President, US and International Business Development of Express Scripts from October 2010 to October 2012 and in both cases, led deal teams to sell the two companies. Ms. Ricciardi was in the commercial division of Pfizer Inc., taking three drugs to launch before being appointed by the Chairman to run Global Business Development. Ms. Ricciardi previously served on the boards of Contrafect (Nasdaq: CFRX), Chimerix (Nasdaq: CMRX), United Drug Healthcare Group, PLC (LSE: UDG) and Sepracor (Nasdaq: SEPR). She was appointed as the executive in residence at Columbia Technology Ventures in January 2020.Ms. Ricciardi earned a Bachelor of Arts degree cum laude in English and Religion from Wesleyan University and an MBA from the University of Chicago Booth School of Management.- Lisa Ricciardi自2014年3月以来一直是我们的董事之一。她目前是爱尔兰都柏林的药物医疗集团的董事会成员并长期担任Sepracor董事会的一员。自2012年7月以来，她做了Davita RX公司（提供全面肾保健服务的制药公司）的顾问。从2010年10月到2012年6月她担任Medco Health Solutions, Inc.的业务发展高级副总裁和 Essex Woodlands Health Ventures合资企业合伙人。她还多次担任Pfizer公司高级管理职位，包括许可和发展部门高级副总裁，执行了超过25个与跨国公司和生物技术公司合作的项目，以及全球制药部门的几个关键的产品发布。她获得了芝加哥大学的工商管理硕士学位和卫斯理大学学士学位。
- Lisa Ricciardi has served as our Chief Executive Officer and President since March 2020 and as a member of our board of directors since March 2019. From July 2018 to October 2019 she served as CEO of Suono Bio, a biotech company based on Langer Labs MIT technology. Prior to her position at Suono Bio, Ms. Ricciardi was a retained executive for BioBusiness Links from November 2015 to June 2018 where she performed interim operating executive and advisory board roles. She served as the Senior Vice President, Global Corporate & Business Development of Foundation Medicine from July 2014 to November 2015 and Senior Vice President, US and International Business Development of Express Scripts from October 2010 to October 2012 and in both cases, led deal teams to sell the two companies. Ms. Ricciardi was in the commercial division of Pfizer Inc., taking three drugs to launch before being appointed by the Chairman to run Global Business Development. Ms. Ricciardi previously served on the boards of Contrafect (Nasdaq: CFRX), Chimerix (Nasdaq: CMRX), United Drug Healthcare Group, PLC (LSE: UDG) and Sepracor (Nasdaq: SEPR). She was appointed as the executive in residence at Columbia Technology Ventures in January 2020.Ms. Ricciardi earned a Bachelor of Arts degree cum laude in English and Religion from Wesleyan University and an MBA from the University of Chicago Booth School of Management.